undamentalytics Newsletter

Metagenomi Therapeutics, Inc. valuation and forecast

Explore the models for Metagenomi Therapeutics, Inc., adjust their assumptions and compare your own valuation with the platform's.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: data-quality checks not passed.

Price vs value

Under review: data-quality checks not passed. We'll show the comparison once resolved.

Analyst recommendations

5 analysts, Oct 2026
Buy480%
Hold120%
Sell00%

Monthly trend

  1. Oct 2026415
  2. Sep 2026415
  3. Aug 2026415

Counts of recommendations published by analysts covering Metagenomi Therapeutics, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Price history

Loading chart…

Third-party market data · may be delayed

MGX valuation questions

How does Fundamentalytics value Metagenomi Therapeutics, Inc.?
We use the models that fit Metagenomi Therapeutics, Inc.'s business and available financial data: growth cash-flow model, forward price-to-sales vs peers. Each model has its own assumptions and data requirements. The calculator explains which models are available and lets you adjust their inputs.

Data: SEC EDGAR filings, retrieved November 1, 2026. Method: how we value companies. Disclosures: research and recommendations disclosure. Back to Metagenomi Therapeutics, Inc.

Compare with peers